Moleculin Biotech (MBRX) Expected to Announce Quarterly Earnings on Friday

Moleculin Biotech (NASDAQ:MBRX) will likely be posting its quarterly earnings results before the market opens on Friday, March 21st. Analysts expect Moleculin Biotech to post earnings of ($1.25) per share for the quarter.

Moleculin Biotech Trading Up 4.8 %

Shares of MBRX stock traded up $0.05 during mid-day trading on Thursday, reaching $1.09. 451,310 shares of the company’s stock traded hands, compared to its average volume of 1,396,514. Moleculin Biotech has a 12 month low of $0.40 and a 12 month high of $7.80. The firm has a 50 day moving average price of $1.38 and a two-hundred day moving average price of $2.04.

Analyst Upgrades and Downgrades

A number of analysts have commented on MBRX shares. Maxim Group cut Moleculin Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th. StockNews.com started coverage on shares of Moleculin Biotech in a report on Thursday, March 13th. They issued a “sell” rating for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of Moleculin Biotech in a report on Monday, March 3rd.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.